Ensuring Fair Access to Care for Inflammatory Bowel Disease: Obstacles, Approaches, and Future Perspectives
-
By
-
Johan Burisch
-
Rupa Banerjee
-
Gillian Watermeyer
-
February 10, 2026
Ensuring Fair Access to Care for Inflammatory Bowel Disease: Obstacles and Strategies
Overview
The global burden of inflammatory bowel disease (IBD) is increasing rapidly, especially in low- and middle-income countries (LMICs), where access to quality care is limited. Disparities exist due to geographic, socioeconomic, racial, and structural factors, necessitating multifaceted strategies to improve equitable care worldwide.
Background
IBD, including Crohn’s disease and ulcerative colitis, has transitioned from a predominantly Western disease to a global health challenge, with cases rising sharply in newly industrialized regions. Managing IBD requires lifelong, multidisciplinary care, which is costly and complex. Access to care is uneven, with patients in LMICs and rural areas facing shortages of specialists and advanced diagnostics, while disadvantaged groups in high-income countries encounter financial and social barriers. Equity in care means addressing these diverse barriers to ensure comparable outcomes for all patients.
Data Highlights
| Region/Group | Access Challenges | Outcomes |
|---|---|---|
| LMICs | Shortages of gastroenterologists, limited diagnostics, poor access to therapies | Delayed diagnosis, limited treatment options |
| Rural areas (USA, Canada) | Few specialists, long travel distances | Lower specialist visits, higher hospitalizations and emergency visits |
| Low socioeconomic status | Financial barriers, delayed therapy initiation | Prolonged corticosteroid use, higher hospitalization rates |
| Ethnic and racial minorities | Late diagnosis, less biologic use, underrepresentation in trials | Worse outcomes, reduced evidence applicability |
Key Findings
- IBD prevalence is rising globally, with significant increases in Asia, Africa, the Middle East, and Latin America.
- Geographic disparities limit access to specialists and advanced diagnostics, especially in LMICs and rural areas.
- Socioeconomic status strongly influences IBD outcomes, with lower SES linked to delayed treatment and higher hospitalizations.
- Ethnic and racial minorities face later diagnoses, reduced access to biologics, and underrepresentation in clinical trials.
- Structural issues such as shortages of IBD nurses, fragmented care, and lack of multidisciplinary teams exacerbate disparities.
- Strategies to improve equity include policy reforms, expanding diagnostic and therapeutic capacity, telemedicine, patient involvement, and cultural competence training.
Clinical Implications
Clinicians should recognize the multifactorial barriers affecting IBD patients, particularly those in underserved regions or disadvantaged groups. Incorporating telemedicine and cost-effective diagnostics can help bridge gaps, while culturally competent care and patient engagement are essential to reduce stigma and diagnostic delays. Policy advocacy is needed to support equitable reimbursement and resource allocation.
Conclusion
Achieving equitable access to IBD care requires coordinated efforts across clinical, policy, and community domains to address geographic, socioeconomic, and structural barriers. Embedding equity into care models and leveraging innovations will be critical to improving outcomes globally.
References
- Global Burden of Disease Study 2017 -- IBD Epidemiology
- Health Equity and Access in IBD Care -- Review Article
Based on findings from:
Equitable access to inflammatory bowel disease care: challenges, strategies, and future directions
Johan Burisch, Rupa Banerjee, Gillian Watermeyer. Journal Of Crohn's And Colitis, 2026.
https://academic.oup.com/ecco-jcc/article/20/Supplement_2/ii11/8489897
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.